Use of assisted-reproduction technology increases the risk of gestational diabetes by about 30%, although the prognosis for these women is similar to that of those who have normal pregnancies, new research presented at the European Association for the Study of Diabetes (EASD) 2015 Meeting indicates.
The use of insulin pumps in patients with difficult-to-treat type 2 diabetes is safe and effective for up to 5 years, a small single-center study suggests. The findings were presented September 17 here at the European Association for the Study of Diabetes (EASD) 2015 Meeting by Priyamvada Singh, MD, of St Vincent Hospital, Worcester, Massachusetts.
Metformin-related vitamin B12 deficiency might contribute to clinically significant peripheral neuropathy in diabetes patients, new research suggests.
Exposure to pesticides significantly increases the risk of type 2 diabetes by nearly 60%, finds an extensive literature review presented at the the European Association for the Study of Diabetes 2015 Meeting last week.
Dapagliflozin (an inhibitor of the subtype 2 of the sodium-glucose transport proteins: SGLT2) alone and in combination with saxagliptin (an dipeptidyl peptidase-4 (DPP-4) inhibitor) has been shown to improve beta cell function and reduce insulin levels by increasing insulin clearance. This result of a comparative trial was reported at the Annual Meeting of the European […]
Insulin degludec/liraglutide has proven to be superior to insulin glargine in hemoglobin A1c reduction, risk of hypoglycemia, and weight reduction in the DUAL V study. This result of the open-label DUAL V trial was reported at the Annual Meeting of the European Association for the Study of Diabetes 2015.
According to the largest study of its kind, higher HbA1c levels are associated with an increased risk of dementia among patients with type 2 diabetes, indicating potential for prevention of dementia with improved glycemic control.
Six-year follow-up data on the use of hyperbaric-oxygen therapy in patients with chronic diabetic foot ulcer shows a significant improvement in long-term survival compared with placebo. The results were presented at the European Association for the Study of Diabetes (EASD) 2015 Meeting, by lead investigator Magnus Löndahl, MD, of Lund University, Sweden.
According to a new research, the risk of pancreatic cancer was not elevated with incretin-based drugs compared with other glucose-lowering therapies.
Glyburide is associated with an increased risk for cancer compared with other diabetes drugs of the sulfonylurea class, new research suggests. Previous observational studies have linked the use of sulfonylureas in general to an increased risk of cancer, but only a few studies have examined the association by type of sulfonylurea, the authors explain.
According to a new study published online August 26 in Circulation, being a smoker and having diabetes increases the relative risk of total mortality and cardiovascular events by about 50%, and quitting smoking can reduce these risks.